GCG and obesity disorder: Its main physiological actions include enhancing glucose-dependent insulin secretion, suppressing postprandial glucagon secretion, slowing gastric emptying and inducing satiety through hypothalamic stimulation.32 Long-acting GLP-1 receptor agonists (GLP-1 RAs) have therefore been engineered for the treatment of T2D and obesity.33–35